| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | S100A16 |
| Uniprot No | Q96FQ6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-103aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSHMSDCYTELEK AVIVLVENFY KYVSKYSLVK NKISKSSFRE MLQKELNHML SDTGNRKAAD KLIQNLDANH DGRISFDEYW TLIGGITGPI AKLIHEQEQQ SSS |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于S100A16重组蛋白的3篇参考文献示例(内容基于公开研究归纳，非真实文献)：
1. **"S100A16 promotes cell proliferation and metastasis in gastric cancer through Wnt/β-catenin pathway"**
- 作者：Liu Y, et al.
- 摘要：研究揭示了S100A16在胃癌组织中的高表达与患者不良预后相关，通过激活Wnt/β-catenin信号通路促进肿瘤细胞增殖和转移。重组S100A16蛋白体外实验证实其调控下游靶基因的作用。
2. **"Recombinant S100A16 protein induces adipocyte differentiation via PPARγ activation"**
- 作者：Fujita K, et al.
- 摘要：利用大肠杆菌表达系统纯化的重组S100A16蛋白，证实其通过结合钙离子并激活PPARγ通路，促进前脂肪细胞分化，为肥胖相关代谢疾病机制提供新见解。
3. **"S100A16 as a novel biomarker for pancreatic ductal adenocarcinoma: Expression analysis using recombinant protein antibodies"**
- 作者：Zhang H, et al.
- 摘要：通过制备重组人S100A16蛋白及其特异性抗体，发现其在胰腺癌组织中显著高表达，且与肿瘤分期正相关，提示其作为诊断标志物的潜力。
(注：以上文献为示例，实际引用请根据具体研究通过PubMed或Google Scholar检索确认。)
S100A16 is a member of the S100 family of calcium-binding proteins, which are characterized by two EF-hand structural domains and involvement in diverse cellular processes such as cell proliferation, differentiation, and inflammation. First identified in 2002. S100A16 (also termed S100-H or FKSG14) is unique among S100 proteins due to its atypical calcium-binding motifs and distinct functional properties. Unlike most S100 proteins that form homodimers, S100A16 primarily exists as a monomer under physiological conditions but can dimerize in a calcium-dependent manner. It is ubiquitously expressed, with elevated levels observed in tissues like the brain, pancreas, and adipose tissue.
Functionally, S100A16 participates in intracellular calcium signaling, cell cycle regulation, and extracellular signaling through interactions with target proteins such as RAGE (receptor for advanced glycation end products). Its role in disease pathogenesis has garnered attention, particularly in cancer, where it exhibits dual oncogenic or tumor-suppressive effects depending on tissue context. For example, S100A16 promotes metastasis in colorectal and breast cancers but inhibits progression in glioblastoma. Additionally, it is implicated in metabolic disorders, including obesity and type 2 diabetes, by regulating adipogenesis and insulin secretion.
Recombinant S100A16 protein, typically produced in prokaryotic (e.g., *E. coli*) or eukaryotic expression systems, enables mechanistic studies of its structure-function relationships, post-translational modifications (e.g., cysteine oxidation), and interactome. However, challenges remain in replicating its native conformation due to aggregation-prone regions and redox-sensitive cysteine residues. Current research focuses on leveraging recombinant S100A16 to develop diagnostic biomarkers and therapeutic strategies, particularly for cancers and metabolic syndromes. Its dynamic regulation and context-dependent roles highlight its potential as a multifunctional mediator in cellular physiology and disease.
×
